Unlocking the Code: Can Molecular Pathology Break Myriad Genetics' Monopoly on Genetic Testing?
Unlocking the Code: Can Molecular Pathology Break Myriad Genetics' Monopoly on Genetic Testing? Price competition and new tech drive fresh interest in challenging established genetic testing models.
Pathways Challenge Legacy Control Unlocking the Code: Can Molecular Pathology Break Myriad Genetics' Monopoly on Genetic Testing? is market disruption through modern diagnostics. Research shows lower costs and broader gene panels can shift provider preferences.
How New Methods Compete Labs leverage advanced sequencing platforms to offer comparable accuracy at reduced prices. Studies indicate payers respond when credible alternatives present clear value. Competition encourages faster reporting and more flexible service terms.
A Simple Takeaway Greater lab diversity encourages better pricing and accelerates patient access to needed tests.
Q&A
Q: What does molecular pathology change in genetic testing? It introduces alternative lab platforms using comparable methods at lower prices.
Q: Why might payers cover these new options? Evidence of cost savings and reliable results supports coverage decisions.
